Opexa Briefs Shareholders on Corporate Update
Opexa Therapeutics holds an informative briefing on both executive and scientific company news.
January 20, 2009
Opexa Therapeutics holds an informative briefing on both executive and scientific company news.
The Australia-based company Mesoblast Limited announces institutional approval to begin the first human clinical trials of adult stem cell treatment for the prevention of osteoarthritis in the knee after acute traumatic injury.
In a controversial ruling, the Scottish company ReNeuron has received authorization to conduct a clinical trial in which patients will be treated for corneal blindness with stem cells harvested from aborted human fetuses.
Scientists in Egypt demonstrate the ability of bone marrow stem cells to treat chronic cardiac disease that is associated with diabetes.
Researchers in Brazil have demonstrated improvement in muscular dystrophy patients following treatment with adult stem cells derived from umbilical cord blood.
Research in the United Kingdom with human-animal hybrid experimentation has ground to a halt due to lack of funding.
Toll Free:
1-800-980-STEM (7836)
Outside or Inside US Call:
1-954-358-3382
Toll Free Fax (US Only):
1-866-755-3951
From Outside US Fax:
1-775-887-1194
Copyright 2024, Stem Cell Insitute Panama. All rights reserved.